3.jpg

Anna Lantz

Anknuten till Forskning

Organisation:

Om mig

Anna Lantz (fd Wallerstedt)

Docent och specialist i Urologi vid Karolinska Universitetssjukhuset i Solna. Forskar inom prostatacancer parallellt med det kliniska arbetet med fokus på optimering av detektion, monitorering samt utvärdering av kirurgisk behandling. 

Avhandling: Outcomes after surgical treatment of localized prostate cancer with focus on urinary incontinence and short term complications

Efter jag avslutat min doktorsexamen var jag postdoktor på Medicinsk Epidemiologi och Biostatistik på Karolinska Institutet inom Stockholm3-gruppen och genomförde som ansvarig (PI) STHLM3AS-studien med målet att förbättra uppföljningen av män med lågrisk-prostatacancer. Under 2019-2020 var jag baserad i New York och arbetade som postdoktor på Mount Sinai Hospital med forskning inom prostatacancer. 

Forskningsbeskrivning

LAPPRO-trial evaluating functional and oncological outcomes after prostate cancer surgery

  • The overarching aim with my research has been to improve patient care for men with prostate cancer. The LAPPRO-trial is a multicentre, prospective controlled trial of men who underwent radical prostatectomy between 2008 and 2011 (n=4003). In this national collaborative study, comprising men from 14 hospitals in Sweden, I have evaluated functional outcomes, such as incontinence, erectile dysfunction and quality of life after radical prostatectomy. I defended my thesis presenting data from the LAPPRO trial in 2015 and have continued my collaboration with the group since then. I am currently leading the work of the 8-year follow-up of the trial.

Principal Investigator for STHLM3AS and STHLM3AS-NorDCaP

  • The latest years, I have focused on evaluating diagnostics and follow up in men with low-risk prostate cancer. Specifically, I analyzed men with low-risk prostate cancer on active surveillance in the STHLM0 database and found that the guidelines for monitoring are not followed. We identified the need for improved active surveillance protocols and thus started the STHLM3-AS with the aim to improve monitoring of men with low-risk prostate cancer, including the Stockholm3-test and MRI. The study included over 300 men and the results, published in JNCI, show that our new proposed protocol leads to higher detection rate of significant prostate cancer including less invasive monitoring. To validate our results, we initiated STHLM3AS NorDCaP including men from Norway, Denmark, Finland and Sweden with the aim to recruit 400 men on active surveillance within 2021. The objective of the study is to validate our results from STHLM3AS and improve surveillance for low risk prostate cancer.

Studies within the STHLM0 database

  • Using the population-based cohort STHLM0, I have been involved in several studies evaluating the effect of drugs and diseases on the risk of being diagnosed with prostate cancer. In 2018 we performed a large population-based historical prospective study using data from STHLM0 and found a reduced risk of prostate cancer among 5-ARI users. We are currently investigating the effect of 5-ARIs on prostate cancer specific mortality.

Mount Sinai Prostate Cancer Cohort, New York

  • In 2019-2020 I was offered a research position at Mount Sinai Hospital in New York City, USA. During my postdoc at Mount Sinai I evaluated diagnostics in prostate cancer using MRI and biomarkers, specifically for men with low risk prostate cancer. In my main publication we created a nomogram for including men into active surveillance rather than curative treatment, in an attempt to increase quality of life and decrease overtreatment of men with clinically insignificant prostate cancer. Our results emphasize that a greater proportion of men with localized prostate cancer can be treated conservatively with active surveillance in a safe way if the selection is optimized. Furthermore, through the collaboration I have been involved in creating a multicenter MRI-database with data from 5 countries, containing 3700 men with prostate cancer that has underwent MRI and targeted biopsies. After my postdoc period I have continued to have close contact with my collegues at Mount Sinai, collaborating in different projects.

 

Pedagogiska meriter

Leadership and pedagogical training

  • 2019 Teaching and Learning in Higher Education Distance (GHPD) Course
  • 2018-19 Head of urological education, Karolinska University Hospital
  • 2017- Teacher for medical students at the Department of Urology in Karolinska Hospital
  • 2016-17 Teacher in Research School for clinicians in Epidemiology, Karolinska Institutet

Teaching experience Around 140 teaching hours at Karolinska University Hospital and Karolinska Institutet. The teaching has involved lectures, seminars and bed side /OR teaching.

Utbildning

  • 2021 Docent (Karolinska Institutet)
  • 2019-2020 Postdoc (Icahn School of Medicine, Mount Sinai Hospital, New York)
  • 2018 Specialistläkare i Urologi
  • 2016-2018 Postdoc (Inst för Medicinsk epidemiologi och biostatistik, Karolinska Institutet)
  • 2015 Medicine Doktor (Inst för Molekylär medicin och kirurgi, Karolinska Institutet)
  • 2008 Leg. läkare (Karolinska Institutet)

Akademiska priser och utmärkelser

  • 2018- SLL Postdoc
  • 2011-2016 SLL Research Resident 
  • 2011 26th Annual EAU Congress in Vienna, Best Poster Presentation Award

Research grants

  • 2020 Åke Wibergs Stiftelse
  • 2020 Karolinska Institutets Research Grant
  • 2020 Svenska sällskapet för medicinsk forskning
  • 2020 Prostatacancerförbundet
  • 2019-2020 Svenska Läkaresällskapets Postdoc
  • 2019 Hirsch resebidrag för kirurger
  • 2018-2019 Postdoc, Stockholm County Council
  • 2017 Grant, Johan Hedins Stiftelse
  • 2011-2016 Research-Resident in Urology, Stockholm County Council
Loading bibliometrics...